DRUG DEVELOPMENT NOTES

drug development report on: Stimulating the innate immune system with the TLR7 agonist PRTX007 Toll like receptors (TLRs) play a key role in the innate immune system by recognising invading pathogens. Once a TLR recognises an invading pathogen they activate immune cell responses. Enhancing the innate immune response may be beneficial to enhance response to viral infections. Activation of the innate immune system is also beneficial in cancer to reverse immunosuppression in the tumour microenvironment and to initiate surveillance. Design a phase 3 clinical trial to determine whether enhancing the innate immune system in this way will help treat: b. Virally-mediated cancers such as Hepatitis C => hepatocellular carcinoma or HPV-related cancers (cervical, vaginal, vulvar, penile, anal and oropharynx).

1. Introduction

2. Trial Design

2.1 Study Type

A multi-center, randomized, double-blind, placebo-controlled (or active comparator-controlled where appropriate), Phase 3 clinical trial.

2.2 Objectives

Primary Objective: To evaluate the overall survival (OS) or progression-free survival (PFS) of patients with virally-mediated cancers treated with PRTX007 as an add-on to standard of care (SOC) or as monotherapy (if SOC is ineffective/unavailable for specific subtypes) versus placebo or SOC alone.
Secondary Objectives:
- To assess the objective response rate (ORR) and duration of response (DoR).
- To evaluate the safety and tolerability profile of PRTX007.
- To assess the impact of PRTX007 on quality of life (QoL).
- To explore changes in immune biomarkers (e.g., T-cell activation, cytokine profiles, viral load, tumor microenvironment markers) in response to PRTX007.

2.3 Patient Population

Inclusion Criteria:
- Adult patients (aged $\ge 18$ years) with histologically or cytologically confirmed virally-mediated cancer (e.g., HCC secondary to chronic Hepatitis C infection, or HPV-related cervical, vaginal, vulvar, penile, anal, or oropharynx carcinoma).
- Patients must have advanced or metastatic disease not amenable to curative surgery or radiation, or have progressed on prior therapy.
- Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
- Eastern Cooperative Oncology Group (ECOG) performance status of $0$ or $1$ .
- Adequate hematologic, renal, and hepatic function.
- Patients with documented active Hepatitis C or HPV infection, where applicable.
Exclusion Criteria:
- Prior treatment with other TLR agonists.
- Active autoimmune disease requiring systemic treatment.
- Any severe concurrent disease that would limit participation or confound results.
- Pregnant or lactating women.

2.4 Sample Size

Approximately $600-800$ patients, allocated $1:1$ or $2:1$ to treatment arms, powered to detect a statistically significant improvement in OS or PFS with PRTX007 (with $80-90\%$ power and a significance level of $\alpha = 0.05$ ).

2.5 Treatment Arms

Arm A (Experimental): PRTX007 at a predetermined optimal dose and schedule (e.g., subcutaneous injection once or twice weekly/monthly) combined with standard of care (SOC) for the specific cancer type (e.g., sorafenib for HCC, platinum-based chemotherapy/immunotherapy for HPV-related cancers) or as monotherapy if SOC is not appropriate.
Arm B (Control): Placebo (matching PRTX007 formulation) combined with SOC, or SOC alone.

2.6 Randomization and Blinding

Patients will be randomized $1:1$ or $2:1$ to either Arm A or Arm B using an interactive web response system (IWRS) or interactive voice response system (IVRS). The study will be double-blinded, meaning both patients and investigators will be unaware of the assigned treatment arm. Placebo will be matched in appearance to PRTX007.

3. Study Procedures and Assessments

3.1 Screening Phase (up to 28 days)

Review of medical history, physical examination, assessment of eligibility criteria.
Baseline imaging (CT/MRI) and blood tests (CBC, chemistry panel, viral load, tumor markers).
Baseline quality of life questionnaires.

3.2 Treatment Phase

PRTX007/placebo and SOC administered according to the assigned arm until disease progression, unacceptable toxicity, or withdrawal of consent.
Regular safety assessments (adverse events, vital signs, lab tests) at each visit.
Tumor assessments every $6-8$ weeks by independent central review.
Immunological assessments (e.g., cytokine panels, immune cell phenotyping) at pre-specified intervals.
QoL assessments every $12$ weeks.

3.3 Follow-up Phase

Post-treatment follow-up for survival for at least $1-2$ years after the last patient's last visit.

4. Statistical Analysis

Primary Endpoint Analysis: Cox proportional hazards model for OS/PFS, Kaplan-Meier method for survival curves. Hazard ratios with $95\%$ confidence intervals will be reported.
Secondary Endpoint Analysis: Descriptive statistics for ORR, DoR, safety, and QoL. Logistic regression or chi-square tests for response rates. Mixed models for QoL changes over time.
Subgroup analyses will be performed for different cancer types (HCC vs. HPV-related), prior therapies, and biomarker status.

5. Ethical Considerations

The protocol will be approved by an Institutional Review Board (IRB) or Ethics Committee (EC).
All patients will provide written informed consent prior to any study procedures.
Data monitoring committee (DMC) will oversee patient safety and efficacy.

6. Expected Outcomes

It is hypothesized that PRTX007 will enhance the innate immune response, leading to improved tumor control, survival, and a favorable safety profile compared to placebo or SOC alone in

SECTION 1

1. Summary of Project

This report outlines the design for a Phase 3 clinical trial to evaluate the efficacy and safety of the Toll-like Receptor 7 (TLR7) agonist PRTX007 in treating virally-mediated cancers, specifically Hepatitis C-associated hepatocellular carcinoma (HCC) and Human Papillomavirus (HPV)-related cancers (cervical, vaginal, vulvar, penile, anal, and oropharynx). The rationale is to enhance the innate immune system to overcome immunosuppression in the tumor microenvironment and initiate tumor surveillance. The proposed project focuses on stimulating the innate immune system using PRTX007, aims to combat viral infections and reverse immunosuppression prevalent in the tumor microenvironment of virally-mediated cancers, thereby initiating effective tumor surveillance. This strategy holds promise for boosting the body’s natural defenses against cancer cells that arise from chronic viral infections. The primary goal is to determine if PRTX007, when added to standard of care (SOC) or used as monotherapy, can significantly improve overall survival (OS) or progression-free survival (PFS) in patients with advanced virally-mediated cancers. Secondary objectives include assessing objective response rate (ORR), duration of response (DoR), safety, and tolerability, as well as evaluating the drug's impact on patients' quality of life (QoL) and exploring changes in key immune biomarkers, such as T-cell activation and cytokine profiles. The research design is a multi-center, randomized, double-blind, placebo-controlled Phase 3 clinical trial, ensuring high-quality evidence by minimizing bias. Approximately $600-800$ adult patients will be enrolled in an experimental arm (PRTX007 plus SOC) or control arm (placebo plus SOC). Regular assessments including tumor imaging (every $6-8$ weeks), safety checks, immunological profiling, and QoL questionnaires will be conducted, with statistical analysis primarily using Cox proportional hazards models and Kaplan-Meier methods for survival endpoints.

2. Rationale and Proposed Impact of Study

Virally-mediated cancers represent a significant global health burden, arising from chronic infections with specific oncogenic viruses. This project specifically targets Hepatitis C Virus (HCV)-associated hepatocellular carcinoma (HCC) and Human Papillomavirus (HPV)-related cancers, including cervical, vaginal, vulvar, penile, anal, and oropharyngeal carcinomas. These cancers are particularly insidious because of the challenges in early detection, treatment resistance, and the profound impact they have on patient quality of life and healthcare systems.

Pathophysiology of the Disease

Hepatocellular Carcinoma (HCC) and HCV: Chronic HCV infection is a major risk factor for HCC. The virus does not directly integrate into the host genome but causes persistent inflammation, oxidative stress, and hepatocyte regeneration, leading to hepatocyte damage, fibrosis, cirrhosis, and eventually malignant transformation. HCV proteins (e.g., Core, NS3, NS5A) induce cellular signaling pathways (e.g., Wnt/ $\beta$ -catenin, MAPK, PI3K/Akt) that promote cell proliferation, inhibit apoptosis, and enhance angiogenesis. The chronic inflammatory microenvironment fuels oncogenesis, making the liver an immunosuppressive environment conducive to tumor growth.
HPV-Related Cancers: High-risk HPV types, particularly HPV16 and HPV18, are etiologically linked to over $90\%$ of cervical cancers and a substantial portion of other anogenital and oropharyngeal cancers. HPV oncogenesis is driven by the sustained expression of two viral oncoproteins, E6 and E7. E6 targets and degrades the tumor suppressor protein p53, thereby abrogating cell cycle checkpoints and promoting cell survival. E7 inactivates the retinoblastoma protein (pRb), leading to uncontrolled cell proliferation. Together, E6 and E7 dysregulate cellular pathways, induce chromosomal instability, and create an immune evasion environment, allowing infected cells to transform and proliferate unchecked. Many HPV-related tumors also exhibit increased PD-L1 expression, indicating a mechanism of immune escape.

Existing Treatments – Pros and Cons

HCC:
- Early Stage: Surgical resection, liver transplantation, locoregional therapies (radiofrequency ablation, transarterial chemoembolization - TACE). Pros: Potentially curative. Cons: Limited to early-stage disease, high recurrence rates, complex patient selection, risk of complications.
- Advanced Stage: Systemic therapies like tyrosine kinase inhibitors (TKIs) such as sorafenib, lenvatinib, and more recently, immune checkpoint inhibitors (ICIs) like atezolizumab-bevacizumab. Pros: Extend survival in advanced disease. Cons: Modest survival benefits, significant side effects (hand-foot skin reaction, hypertension, diarrhea), primary and secondary resistance mechanisms, high cost, ICIs have varying response rates and can cause immune-related adverse events.
HPV-Related Cancers:
- Early Stage (e.g., cervical): Surgery (conization, hysterectomy), radiation therapy. Pros: Highly effective for localized disease. Cons: Can impact fertility and sexual function, risk of long-term side effects from radiation.
- Advanced Stage: Chemotherapy (platinum-based), radiation, often combined with immunotherapy (e.g., pembrolizumab for recurrent/metastatic HPV-positive head and neck squamous cell carcinoma). Pros: Improve response rates and survival in advanced settings. Cons: Systemic toxicities of chemotherapy, radiation-induced damage, ICIs are expensive and not universally effective.
Common Challenges: Both cancer types face issues with treatment resistance, severe side effects, and heterogeneous patient responses. The immunosuppressive tumor microenvironment often limits the effectiveness of current therapies, including immunotherapies, by allowing cancer cells to evade immune destruction. There is a clear unmet need for novel agents that can overcome these challenges and enhance anti-tumor immunity.

Impact on the Individual & Health System

Individual Impact: Diagnosis is devastating, leading to declines in physical and mental health due to symptoms and treatment side effects, severely compromising quality of life. Survivorship issues like depression and anxiety are common, and the emotional and financial strain extends to families. For specific cancers, there can be significant psychological distress related to body image and sexual function.
Health System Impact: Virally-mediated cancers impose an immense economic burden. Costs include diagnosis, intensive treatment regimens, managing side effects, palliative care, and long-term follow-up. Loss of productivity strains national economies, and public health programs for screening and vaccination require substantial investment and infrastructure. The complexity of these diseases demands specialized multidisciplinary teams, taxing limited healthcare resources.

Overall Burden of Disease

Globally, virally-mediated cancers account for a significant proportion of all cancer cases. For instance, HPV is responsible for over $5\%$ of all human cancers, with cervical cancer being the fourth most common cancer in women worldwide. HCC is among the leading causes of cancer-related death globally, strongly linked to chronic viral hepatitis. The burden is disproportionately high in low- and middle-income countries. Even in high-income countries, significant challenges remain due to late diagnosis, aggressive disease biology, and treatment resistance. The existence of these cancers underscores the need for continuous research into novel therapeutic strategies. Enhancing the innate immune system, as proposed with PRTX007, offers a promising approach by leveraging the body's own defenses, potentially leading to more durable responses and a better quality of life for affected individuals, thereby alleviating a substantial part of this global disease burden. Investigating PRTX007 is thus highly warranted due to the critical unmet need for more effective, tolerable, and accessible treatments for these devastating diseases.

3. Trial Design

3.1 Study Type

A multi-center, randomized, double-blind, placebo-controlled (or active comparator-controlled where appropriate), Phase 3 clinical trial.

3.2 Objectives

Primary Objective: To evaluate the overall survival (OS) or progression-free survival (PFS) of patients with virally-mediated cancers treated with PRTX007 as an add-on to standard of care (SOC) or as monotherapy (if SOC is ineffective/unavailable for specific subtypes) versus placebo or SOC alone.
Secondary Objectives:
- To assess the objective response rate (ORR) and duration of response (DoR).
- To evaluate the safety and tolerability profile of PRTX007.
- To assess the impact of PRTX007 on quality of life (QoL).
- To explore changes in immune biomarkers (e.g., T-cell activation, cytokine profiles, viral load, tumor microenvironment markers) in response to PRTX007.

3.3 Patient Population

Inclusion Criteria:
- Adult patients (aged $\ge 18$ years) with histologically or cytologically confirmed virally-mediated cancer (e.g., HCC secondary to chronic Hepatitis C infection, or HPV-related cervical, vaginal, vulvar, penile, anal, or oropharynx carcinoma).
- Patients must have advanced or metastatic disease not amenable to curative surgery or radiation, or have progressed on prior therapy.
- Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
- Eastern Cooperative Oncology Group (ECOG) performance status of $0$ or $1$ .
- Adequate hematologic, renal, and hepatic function.
- Patients with documented active Hepatitis C or HPV infection, where applicable.
Exclusion Criteria:
- Prior treatment with other TLR agonists.
- Active autoimmune disease requiring systemic treatment.
- Any severe concurrent disease that would limit participation or confound results.
- Pregnant or lactating women.

3.4 Sample Size

3.5 Treatment Arms

Arm A (Experimental): PRTX007 at a predetermined optimal dose and schedule (e.g., subcutaneous injection once or twice weekly/monthly) combined with standard of care (SOC) for the specific cancer type (e.g., sorafenib for HCC, platinum-based chemotherapy/immunotherapy for HPV-related cancers) or as monotherapy if SOC is not appropriate.
Arm B (Control): Placebo (matching PRTX007 formulation) combined with SOC, or SOC alone.

3.6 Randomization and Blinding

4. Study Procedures and Assessments

4.1 Screening Phase (up to 28 days)

Review of medical history, physical examination, assessment of eligibility criteria.
Baseline imaging (CT/MRI) and blood tests (CBC, chemistry panel, viral load, tumor markers).
Baseline quality of life questionnaires.

4.2 Treatment Phase

PRTX007/placebo and SOC administered according to the assigned arm until disease progression, unacceptable toxicity, or withdrawal of consent.
Regular safety assessments (adverse events, vital signs, lab tests) at each visit.
Tumor assessments every $6-8$ weeks by independent central review.
Immunological assessments (e.g., cytokine panels, immune cell phenotyping) at pre-specified intervals.
QoL assessments every $12$ weeks.

4.3 Follow-up Phase

Post-treatment follow-up for survival for at least $1-2$ years after the last patient's last visit.

5. Statistical Analysis

Primary Endpoint Analysis: Cox proportional hazards model for OS/PFS, Kaplan-Meier method for survival curves. Hazard ratios with $95\%$ confidence intervals will be reported.
Secondary Endpoint Analysis: Descriptive statistics for ORR, DoR, safety, and QoL. Logistic regression or chi-square tests for response rates. Mixed models for QoL changes over time.
Subgroup analyses will be performed for different cancer types (HCC vs. HPV-related), prior therapies, and biomarker status.

6. Ethical Considerations

The protocol will be approved by an Institutional Review Board (IRB) or Ethics Committee (EC).
All patients will provide written informed consent prior to any study procedures.
Data monitoring committee (DMC) will oversee patient safety and efficacy.

7. Expected Outcomes

It is hypothesized that PRTX007 will enhance the innate immune response, leading to improved tumor control, survival, and a favorable safety profile compared to placebo or SOC alone in

1. Introduction

2. Project Details

2.1 Research Plan - Background

Theoretical, Empirical, and Conceptual Basis

The innate immune system serves as the first line of defense against pathogens and plays a critical role in recognizing and eliminating aberrant cells, including cancer cells. Toll-like Receptors (TLRs) are a class of pattern recognition receptors (PRRs) that are central to innate immunity, sensing conserved molecular patterns associated with pathogens (PAMPs) or damaged host cells (DAMPs). TLR7, specifically, recognizes single-stranded RNA (ssRNA), a common signature of RNA viruses. Upon activation, TLR7 initiates intracellular signaling cascades, primarily through the MyD88 adaptor protein, leading to the activation of transcription factors such as NF- $\kappa$ B and IRF7. This activation culminates in the robust production of type I interferons (IFN- $\alpha$ , IFN- $\beta$ ) and various pro-inflammatory cytokines (e.g., IL-6, IL-12, TNF- $\alpha$ ). These cytokines are crucial for bridging innate and adaptive immunity, promoting immune cell activation, differentiation, and migration, and enhancing antigen presentation. In the context of cancer, particularly virally-mediated cancers, chronic viral infection often leads to a profoundly immunosuppressive tumor microenvironment (TME) characterized by immune cell exhaustion, an abundance of suppressive cells (e.g., regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs)), and checkpoints like PD-1/PD-L1. The conceptual basis for PRTX007 is that stimulating TLR7 can 'reawaken' or 're-educate' the innate immune system within this suppressive TME, converting it into an immune-stimulatory environment capable of driving effective anti-tumor adaptive immune responses and initiating tumor surveillance.

Pathophysiology of the Disease

Hepatocellular Carcinoma (HCC) and HCV: Chronic HCV infection is a major risk factor for HCC. The virus does not directly integrate into the host genome but causes persistent inflammation, oxidative stress, and hepatocyte regeneration, leading to hepatocyte damage, fibrosis, cirrhosis, and eventually malignant transformation. HCV proteins (e.g., Core, NS3, NS5A) induce cellular signaling pathways (e.g., Wnt/ $\beta$ -catenin, MAPK, PI3K/Akt) that promote cell proliferation, inhibit apoptosis, and enhance angiogenesis. The chronic inflammatory microenvironment fuels oncogenesis, making the liver an immunosuppressive environment conducive to tumor growth.
HPV-Related Cancers: High-risk HPV types, particularly HPV16 and HPV18, are etiologically linked to over $90\%$ of cervical cancers and a substantial portion of other anogenital and oropharyngeal cancers. HPV oncogenesis is driven by the sustained expression of two viral oncoproteins, E6 and E7. E6 targets and degrades the tumor suppressor protein p53, thereby abrogating cell cycle checkpoints and promoting cell survival. E7 inactivates the retinoblastoma protein (pRb), leading to uncontrolled cell proliferation. Together, E6 and E7 dysregulate cellular pathways, induce chromosomal instability, and create an immune evasion environment, allowing infected cells to transform and proliferate unchecked. Many HPV-related tumors also exhibit increased PD-L1 expression, indicating a mechanism of immune escape.

Preclinical Studies and Background Evidence

Preclinical research has extensively supported the potential of TLR7 agonists in cancer therapy. In vitro studies with PRTX007 (or structurally similar TLR7 agonists) have demonstrated direct activation of immune cells such as plasmacytoid dendritic cells (pDCs), B cells, and monocytes, leading to a significant increase in the production of key cytokines, including IFN- $\alpha$ , IL-12, and TNF- $\alpha$ . These studies have also shown enhanced antigen presentation capabilities of TLR7-activated dendritic cells, a critical step for priming T-cell responses. Furthermore, various in vivo animal models have provided compelling evidence for the efficacy and safety profile of TLR7 agonists. In syngeneic mouse models of cancer, including those relevant to virally-mediated cancers (e.g., DEN-induced HCC models, or HPV E6/E7-driven tumor models), systemic or local administration of TLR7 agonists has been shown to: 1) significantly inhibit tumor growth and metastasis; 2) prolong overall survival; 3) induce robust anti-tumor immunity characterized by increased infiltration of CD8+ cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells into the tumor microenvironment; 4) reduce the presence of immunosuppressive cells like Tregs and MDSCs within tumors; and 5) upregulate major histocompatibility complex (MHC) class I expression on tumor cells, rendering them more visible to immune effector cells. Importantly, these studies have also indicated synergistic anti-tumor effects when TLR7 agonists are combined with other therapeutic modalities, such as chemotherapy or immune checkpoint inhibitors, suggesting that PRTX007 could act as a potent sensitizer to existing treatments. Safety assessments in these animal models have generally shown acceptable toxicity profiles for the doses and schedules that demonstrated efficacy, providing a foundation for clinical translation. The ability of TLR7 stimulation to directly activate immune cells and remodel the TME from immunosuppressive to immunostimulatory, as evidenced by these robust preclinical findings, provides the strong background evidence that PRTX007 is a feasible and promising therapeutic agent for virally-mediated cancers.

2.2 Research Plan - Aims

Aim: To determine the efficacy and safety of the Toll-Like Receptor 7 (TLR7) agonist PRTX007 in patients with advanced virally-mediated cancers.

Research Question: Does PRTX007, when administered as an add-on to standard of care (SOC) or as monotherapy, significantly improve overall survival (OS) or progression-free survival (PFS) in patients with advanced Hepatitis C-associated hepatocellular carcinoma (HCC) or Human Papillomavirus (HPV)-related cancers compared to placebo or SOC alone?

Hypotheses:

Primary Hypothesis: Treatment with PRTX007 combined with SOC, or as monotherapy where appropriate, will lead to a statistically significant improvement in OS or PFS in patients with advanced virally-mediated cancers compared to placebo plus SOC or SOC alone.
Secondary Hypotheses:
- PRTX007 treatment will result in a superior objective response rate (ORR) and a longer duration of response (DoR).
- PRTX007 will demonstrate a favorable safety and tolerability profile, consistent with its mechanism of action.
- Patients receiving PRTX007 will experience improvements in their quality of life (QoL).
- PRTX007 administration will induce measurable beneficial changes in immune biomarkers, including enhanced T-cell activation, a more favorable cytokine profile, reduction in viral load (where applicable), and a shift in tumor microenvironment markers indicative of reduced immunosuppression and increased anti-tumor activity.

2.3 Impact Statement

The successful outcome of this Phase 3 clinical trial investigating PRTX007 for virally-mediated cancers could have a profound and multifaceted impact on individuals, healthcare systems, and society as a whole. Currently, virally-mediated cancers such as HCC and HPV-related malignancies impose an immense burden, characterized by high morbidity and mortality, often aggressive disease progression, and significant physical and emotional distress for patients and their families.

On Individuals:

For patients diagnosed with advanced virally-mediated cancers, the personal impact is devastating. A successful trial demonstrating improved overall survival or progression-free survival with PRTX007 would offer a new beacon of hope, extending lives and potentially enhancing the quality of life (QoL) through better disease control and symptom management. Patients might experience reduced tumor burden, alleviated pain, improved organ function, and prolonged periods of stability, allowing them more time with their loved ones and a better ability to participate in daily activities. Beyond survival, the addition of a novel immunotherapy agent like PRTX007 could potentially offer a more tolerable treatment option, especially if it leads to synergy with existing SOC, allowing for reduced doses or duration of chemotherapy with its associated debilitating side effects. Psychologically, patients and their families would benefit from the prospect of a more effective treatment, mitigating the chronic stress, anxiety, and depression often associated with a terminal cancer diagnosis and providing a greater sense of agency in their fight against the disease.

On Health Systems and Societal Impact:

Virally-mediated cancers place a tremendous economic strain on healthcare systems globally. The costs associated with diagnosis, complex treatment regimens (including surgery, radiation, and expensive systemic therapies), managing severe side effects, palliative care, and long-term follow-up are substantial. If PRTX007 demonstrates significant improvements in survival and durability of response, it could lead to substantial reductions in these costs over time by decreasing the need for repeated treatments, managing fewer complications from advanced disease, and potentially reducing the extent of palliative care required. Furthermore, by improving patient outcomes, PRTX007 could reduce productivity losses from premature deaths and chronic illness, contributing positively to national economies. Public health initiatives, which often focus on vaccination and screening to prevent these cancers, would be complemented by effective treatment options for those who still develop the disease. A successful trial would also validate a novel immunotherapeutic strategy leveraging innate immunity, opening new avenues for drug development and research in oncology beyond traditional approaches. This could foster a more robust landscape of treatment options, making a substantial contribution to the global effort to combat cancer and alleviating a significant portion of the global disease burden, particularly in regions where these cancers are highly prevalent and access to advanced care is limited. The societal impact extends to fostering healthier communities, reducing the emotional and financial strain on families, and supporting a more productive workforce while advancing scientific understanding of cancer immunology.

3. Trial Design

3.1 Study Type

A multi-center, randomized, double-blind, placebo-controlled (or active comparator-controlled where appropriate), Phase 3 clinical trial.

3.2 Objectives

Primary Objective: To evaluate the overall survival (OS) or progression-free survival (PFS) of patients with virally-mediated cancers treated with PRTX007 as an add-on to standard of care (SOC) or as monotherapy (if SOC is ineffective/unavailable for specific subtypes) versus placebo or SOC alone.
Secondary Objectives:
- To assess the objective response rate (ORR) and duration of response (DoR).
- To evaluate the safety and tolerability profile of PRTX007.
- To assess the impact of PRTX007 on quality of life (QoL).
- To explore changes in immune biomarkers (e.g., T-cell activation, cytokine profiles, viral load, tumor microenvironment markers) in response to PRTX007.

3.3 Patient Population

Inclusion Criteria:
- Adult patients (aged $\ge 18$ years) with histologically or cytologically confirmed virally-mediated cancer (e.g., HCC secondary to chronic Hepatitis C infection, or HPV-related cervical, vaginal, vulvar, penile, anal, or oropharynx carcinoma).
- Patients must have advanced or metastatic disease not amenable to curative surgery or radiation, or have progressed on prior therapy.
- Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
- Eastern Cooperative Oncology Group (ECOG) performance status of $0$ or $1$ .
- Adequate hematologic, renal, and hepatic function.
- Patients with documented active Hepatitis C or HPV infection, where applicable.
Exclusion Criteria:
- Prior treatment with other TLR agonists.
- Active autoimmune disease requiring systemic treatment.
- Any severe concurrent disease that would limit participation or confound results.
- Pregnant or lactating women.

3.4 Sample Size

3.5 Treatment Arms

Arm A (Experimental): PRTX007 at a predetermined optimal dose and schedule (e.g., subcutaneous injection once or twice weekly/monthly) combined with standard of care (SOC) for the specific cancer type (e.g., sorafenib for HCC, platinum-based chemotherapy/immunotherapy for HPV-related cancers) or as monotherapy if SOC is not appropriate.
Arm B (Control): Placebo (matching PRTX007 formulation) combined with SOC, or SOC alone.

3.6 Randomization and Blinding

4. Study Procedures and Assessments

4.1 Screening Phase (up to 28 days)

Review of medical history, physical examination, assessment of eligibility criteria.
Baseline imaging (CT/MRI) and blood tests (CBC, chemistry panel, viral load, tumor markers).
Baseline quality of life questionnaires.

4.2 Treatment Phase

PRTX007/placebo and SOC administered according to the assigned arm until disease progression, unacceptable toxicity, or withdrawal of consent.
Regular safety assessments (adverse events, vital signs, lab tests) at each visit.
Tumor assessments every $6-8$ weeks by independent central review.
Immunological assessments (e.g., cytokine panels, immune cell phenotyping) at pre-specified intervals.
QoL assessments every $12$ weeks.

4.3 Follow-up Phase

Post-treatment follow-up for survival for at least $1-2$ years after the last patient's last visit.

5. Statistical Analysis

Primary Endpoint Analysis: Cox proportional hazards model for OS/PFS, Kaplan-Meier method for survival curves. Hazard ratios with $95\%$ confidence intervals will be reported.
Secondary Endpoint Analysis: Descriptive statistics for ORR, DoR, safety, and QoL. Logistic regression or chi-square tests for response rates. Mixed models for QoL changes over time.
Subgroup analyses will be performed for different cancer types (HCC vs. HPV-related), prior therapies, and biomarker status.

6. Ethical Considerations

The protocol will be approved by an Institutional Review Board (IRB) or Ethics Committee (EC).
All patients will provide written informed consent prior to any study procedures.
Data monitoring committee (DMC) will oversee patient safety and efficacy.

7. Expected Outcomes

It is hypothesized that PRTX007 will enhance the innate immune response, leading to improved tumor control, survival, and a favorable safety profile compared to placebo or SOC alone in